The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

Meanwhile, Tango tries again in PRMT5.

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

Investors will hope for a JP Morgan buying spree, while readouts could come from Kura, Allogene and MacroGenics.

Syndax scored the first menin approval, but Kura is first with a licensing deal.